Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult

Sarepta Therapeutics (SRPT) announced a significant restructuring, including 500 layoffs (36% of its workforce) and $400 million in expense cuts, following two patient deaths linked to its gene therapy Elevidys, which will now carry an FDA warning. Despite Q2 sales missing forecasts and anticipated reduced Elevidys usage, Sarepta's stock surged over 35% late Wednesday, suggesting investor approval for the "necessary and expected" cost-cutting measures amidst the safety concerns.

Analysis

Sarepta Therapeutics (SRPT) is undergoing a significant operational and financial restructuring, driven by severe safety concerns surrounding its key gene therapy, Elevidys. The company announced 500 layoffs, representing 36% of its workforce, and a plan to cut $400 million in expenses. This move follows two patient deaths from acute liver failure, which has prompted the FDA to add a warning to the drug's label. The company's financial performance already shows signs of pressure, with second-quarter total sales of $513 million and Elevidys sales of $282 million both missing consensus forecasts of $529 million and $298 million, respectively. An RBC Capital Markets analyst noted that while the restructuring was "necessary and expected," sharp reductions in Elevidys use are anticipated in the second half of the year. Despite the negative catalysts of patient deaths, an impending FDA warning, and a sales miss, the market reacted with a more than 35% surge in the stock price, indicating that investors are heavily prioritizing the aggressive cost-cutting measures as a means to stabilize the company's financial health amid the product's commercial challenges.

Key Decisions for Investors

• Investors should weigh the market's positive reaction to the $400 million cost-cutting plan against the fundamental headwinds of a new FDA warning label and weakening sales for Elevidys.
• Monitor future revenue reports closely, as analyst commentary points to 'sharp reductions in use' for Elevidys in the second half, which will be a critical test for the sustainability of the recent stock rally.
• The significant restructuring may present a new, leaner investment case for the company, but the overhang from the Elevidys safety issues introduces substantial long-term risk to its primary growth driver.